APPLY TREATMENT TO CLINICAL SYNDROMES
Chlamydia and Genital Warts
Chlamydia treatment aims to eradicate bacterial infection, prevent complications, and interrupt transmission. Genital wart treatment removes visible HPV-associated lesions but does not reliably eradicate the underlying viral infection.
These different goals shape medication selection, counseling, and follow-up (Smith & Honeywell, 2026).
Diagnose Chlamydial Infection
Chlamydia is frequently asymptomatic. When symptoms occur, they may include urethral or cervical discharge, dysuria, bleeding, or pelvic discomfort.
Nucleic acid amplification testing is preferred. Collect specimens according to anatomy and exposure rather than relying on gender identity to determine the testing site.
Pelvic pain, cervical motion tenderness, testicular pain, or systemic illness requires assessment for a more complicated syndrome. An uncomplicated chlamydia regimen is insufficient for conditions such as pelvic inflammatory disease (Smith & Honeywell, 2026).
Select Chlamydia Treatment
For nonpregnant adolescents and adults with uncomplicated infection, doxycycline 100 mg orally twice daily for seven days is preferred.
Azithromycin 1 g orally once is an alternative when adherence to a multidose regimen is a substantial concern, but effectiveness is lower for rectal infection. Pregnancy changes selection; azithromycin 1 g orally once is a recommended regimen.
Assess concurrent infections and whether additional testing or treatment is needed (Centers for Disease Control and Prevention [CDC], 2021a).
Prevent Reinfection
Evaluate and treat partners with sexual contact during the preceding 60 days. The most recent partner should be addressed even when contact occurred earlier.
Expedited partner therapy may be appropriate when timely partner evaluation is unlikely and local law permits. Provide instructions about allergies, administration, and symptoms requiring direct assessment.
Patients should avoid sexual contact until seven days after single-dose treatment or until completion of a seven-day regimen, symptoms resolve, and partners have been treated. Test for HIV, gonorrhea, and syphilis according to exposure history. Retest approximately three months after treatment. In pregnancy, perform a test of cure at about four weeks (CDC, 2021a).
Persistent symptoms require reassessment of adherence, reinfection, an alternative diagnosis, and complications. Testing too early can detect residual nucleic acid and create a misleading result (Smith & Honeywell, 2026).
Evaluate Genital Warts
Most external genital warts are diagnosed clinically. Atypical, pigmented, indurated, bleeding, ulcerated, or treatment-resistant lesions may require biopsy.
Treatment selection depends on lesion location, number, size, pregnancy, immune status, patient preference, and ability to apply medication correctly. Patient-applied treatments are intended for identified, accessible external lesions (Smith & Honeywell, 2026).
Patient-Applied Treatment
Imiquimod: The 5% cream is applied at bedtime three times weekly for up to sixteen weeks. The 3.75% cream is applied nightly for up to eight weeks. Wash the area 6–10 hours after application.
Podofilox 0.5%: Apply twice daily for three days, followed by four treatment-free days. Repeat for up to four cycles. Limit treatment to 10 cm² of wart area and 0.5 mL per day. It is contraindicated in pregnancy.
Both can cause local irritation. Demonstrate which lesions to treat and explain when treatment should be interrupted for significant reactions (CDC, 2021b).
Sinecatechins 15% ointment is applied three times daily until the warts clear, for no longer than 16 weeks. It is not recommended for immunocompromised patients, and pregnancy safety is not established. Avoid sexual contact while the ointment is on the skin because it can weaken condoms and diaphragms and can cause local reactions (CDC, 2021b).
Clinician-Administered Treatment
Cryotherapy, surgical removal, and carefully applied caustic treatments are options when lesion characteristics or patient factors favor office treatment.
Pregnancy and lesions involving the cervix, urethra, or internal anal canal require a site-specific approach. Avoid assuming that a treatment suitable for external skin can be used on internal mucosal lesions (Smith & Honeywell, 2026).
Explain Treatment Limits and Follow-Up
Visible wart clearance does not establish elimination of HPV or guarantee that recurrence will not occur. Reassess response and local adverse effects during treatment.
HPV vaccination prevents new infections from covered types; it does not treat existing warts. Continue indicated cervical screening according to the patient’s history and screening recommendations.
Counseling should be factual and nonjudgmental. The appearance of warts does not reliably identify when infection was acquired (Smith & Honeywell, 2026).
Related YourDNP Resources
Content last reviewed:
References
Centers for Disease Control and Prevention. (2021a, July 22). Chlamydial infections. Sexually Transmitted Infections Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm
Centers for Disease Control and Prevention. (2021b, July 22). Human papillomavirus (HPV) infection: Anogenital warts. Sexually Transmitted Infections Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/anogenital-warts.htm
Smith, U. D., & Honeywell, M. S. (2026). Sexually transmitted infections. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.